As a leader in heart valves for over 60 years, Edwards Lifesciences is dedicated to providing you a destination for the latest transcatheter heart valve information, tools, resources, and innovative solutions.

PARTNER 3 low-risk trial 5 year data

Data from the PARTNER 3 trial continues to prove the Edwards SAPIEN 3 platform is the choice for lifetime management – from the index procedure and beyond.

  • Life: The only transcatheter heart valve with 1% death or disabling stroke at 1 year
  • Time: The only transcatheter heart valve with 90% survival at 5 years, similar to surgery
  • Management: The only transcatheter heart valve with a THV-in-THV indication for high-risk patients

Built for now and what's next

Edwards SAPIEN platform: The move for lifetime management

The first valve choice matters. From outstanding outcomes and excellent durability* today to facilitating future interventions tomorrow, the SAPIEN platform is designed to deliver a TAVR experience an implanter can count on.

Explore Edwards SAPIEN platform for lifetime management

*Propensity matched analysis of intermediate risk patients using VARC-3 definitions of SVD and SVD related BVF at 5 years.

Training and education programs

We offer training on the safe and effective use of our technology, and education programs designed to optimize procedures to better serve your patients.

Review tools

Access the resource library

The resource library contains the latest data, patient guides, best practices and additional materials to help you and your Heart Team stay current and well-informed.

Get TAVR Resources

ACC/AHA Guideline expands TAVR as a Class I recommendation

The ACC/AHA released key updates in their 2020 Guideline for Valvular Heart Disease, including recommendations for the treatment of severe symptomatic aortic stenosis and transcatheter valve repair/implantation for patients. Have these guidelines readily available for your team.

Your first-time valve choice today affects your patients’ treatment options tomorrow1

With patients of all ages living longer and having high expectations for their quality of life, lifetime management is increasingly important.

See the data

Medical information request

Edwards is committed to providing healthcare professionals with accurate, unbiased, and balanced evidence-based product information in order to support clinical decision-making and facilitate better patient outcomes.

Request Transcatheter Heart Valve Medical Information

Research and education grants

Through its educational and research grant programs, Edwards is committed to supporting independent programs that further clinical knowledge, scientific exchange, medical education and delivery of effective therapies for structural heart disease and critical care monitoring, and is further committed to supporting independent research in the area of valve science and hemodynamic monitoring in order to enhance scientific knowledge for the purpose of extending and enhancing human life.

Go to the Edwards Lifesciences Grant portal

Stay connected

Be the first to receive the latest news in transcatheter heart valves, including event announcements.

References:   1. De Backer O, Landes U, Fuchs A, et al. Coronary access after TAVR-in-TAVR as evaluated by multidetector computed tomography. JACC Cardiovasc Interv. 2020; 13(21):2528-2538.